Moderna 8-K
PositiveDebt financing
Credit amendment cuts initial and delayed-draw term-loan margins 75 bp and extends maturity to November 2031.
Filed 2026-11-16 17:19 ET
- 1.01 Entry into a Material Agreement
- 2.03 Creation of a Financial Obligation
- 9.01 Financial Statements and Exhibits
Summary
Credit agreement amendment effective 11/09/2026. Moderna lowered interest margins on its initial and delayed-draw term loans and extended their maturity, reducing borrowing costs and pushing out repayment.
Key Figures
- Interest margins fell 75 bp: for loans bearing interest at a forward-looking term rate derived from the Secured Overnight Financing Rate, from 5.50% to 4.75% per annum; for base-rate loans, from 4.50% to 3.75%.
- Loan maturity extended from 11/24/2030 to 11/24/2031. Availability for the $400M first tranche and $500M remaining tranche of delayed-draw commitments was extended to 11/24/2029; borrowings remain subject to credit-agreement conditions and earlier termination. The $900M in commitments is ≈25% of Moderna’s $3.55B total debt at 9/30/2026 (Q3 2026 10-Q).
- Guarantees and collateral security remain in effect.
Get emails when companies you follow file: email digest settings.
The summary is written by an AI model reading the filing.
Model 005 · prompt v192 · 2026-11-17 15:43:59Z